Finerenone Offered Safer Renal Profile Than Spironolactone
New meta-analysis reveals a lower risk of acute kidney injury when using finerenone compared to older mineralocorticoid antagonists.
Updated on Oct. 10, 2026 in Heart Disease
Live Poll
Do you generally trust that newer medical treatments are safer than established options?
A network meta-analysis of six clinical trials found that finerenone provides a superior renal safety profile compared to spironolactone for patients with heart failure. Researchers reported that spironolactone carried a significantly higher risk of acute kidney injury in these patient populations.
Why it matters
Identifying medications with lower risks of kidney complications is critical for managing heart failure patients, as renal health often dictates the long-term viability of specific treatment regimens. This analysis helps clinicians navigate the safety tradeoffs between different mineralocorticoid receptor antagonists.
The analysis of 1,066 records across six comparative trials showed spironolactone had a risk ratio of 1.34 for acute kidney injury versus eplerenone. Finerenone demonstrated a trend toward reduced injury risk at doses ranging from 7.5 mg to 20 mg.
The details
Researchers performed a PRISMA-guided network meta-analysis on 17 pairwise comparisons derived from seven treatment arms. The study ranked finerenone as having a better renal safety profile than spironolactone, which ranked lowest among the three treatments analyzed.
Timeline
October 2026 marked the formal publication of the research findings.
Health Landscape
This study updates the safety evidence within the broader framework of mineralocorticoid receptor antagonist therapy guidelines. It signifies a potential shift in clinical practice toward prioritizing renal safety metrics when selecting treatments for heart failure patients.
Patients currently prescribed mineralocorticoid receptor antagonists for heart failure should discuss renal safety concerns with their healthcare provider to ensure their treatment is optimized. This data helps medical teams select medications that may reduce the likelihood of experiencing acute kidney injury.
The takeaway
Clinicians and patients should evaluate the specific renal risk profiles of heart failure medications to minimize side effects during long-term therapy. Future research is expected to further refine these comparisons through direct clinical testing.
Further reading
Learn more about evolving treatment standards in our Heart Disease section.
Source note: This article includes information reported by Hcplive.
Live Poll
Do you generally trust that newer medical treatments are safer than established options?
